California State Teachers Retirement System lowered its stake in shares of Insys Therapeutics, Inc. (NASDAQ:INSY) by 8.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,544 shares of the specialty pharmaceutical company’s stock after selling 3,700 shares during the period. California State Teachers Retirement System owned 0.06% of Insys Therapeutics worth $538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its position in shares of Insys Therapeutics by 4.5% during the second quarter. The Manufacturers Life Insurance Company now owns 21,576 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 938 shares during the last quarter. State Street Corp raised its position in shares of Insys Therapeutics by 3.4% during the second quarter. State Street Corp now owns 471,514 shares of the specialty pharmaceutical company’s stock valued at $5,966,000 after buying an additional 15,570 shares during the last quarter. Royal Bank of Canada raised its position in shares of Insys Therapeutics by 100.9% during the second quarter. Royal Bank of Canada now owns 13,695 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 6,877 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Insys Therapeutics by 2.8% during the second quarter. Goldman Sachs Group Inc. now owns 137,453 shares of the specialty pharmaceutical company’s stock valued at $1,738,000 after buying an additional 3,785 shares during the last quarter. Finally, Voya Investment Management LLC bought a new stake in shares of Insys Therapeutics during the second quarter valued at approximately $149,000. Hedge funds and other institutional investors own 25.62% of the company’s stock.

Insys Therapeutics, Inc. (NASDAQ INSY) opened at $5.37 on Wednesday. Insys Therapeutics, Inc. has a fifty-two week low of $4.10 and a fifty-two week high of $15.02.

Several equities research analysts have recently issued reports on INSY shares. Jefferies Group reduced their price objective on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Zacks Investment Research upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price objective on the stock in a research report on Wednesday, October 18th. Royal Bank Of Canada set a $8.00 price objective on shares of Insys Therapeutics and gave the company a “buy” rating in a research report on Friday, October 27th. Oppenheimer reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Monday, October 30th. Finally, BidaskClub upgraded shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 26th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $9.38.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/06/insys-therapeutics-inc-insy-stake-lessened-by-california-state-teachers-retirement-system.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Stock Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related stocks with our FREE daily email newsletter.